Endocannabinoids, metabolic regulation, and the role of diet

Nutrition Research

Volumn 28, Issue 10, 2008, Pages 641-650

  Carr, Timothy P ^a   Jesch, Elliot D ^a   Brown, Andrew W ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Bone; Cardiovascular; Dietary fats; Endocannabinoid receptors; Endocannabinoids; Energy metabolism; Metabolic regulation; Review

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ANANDAMIDE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID SYNTHASE; GLUCOSE; GLUCOSE TRANSPORTER 4; LIPOPROTEIN LIPASE; NOLADIN ETHER; RIMONABANT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; VANILLOID RECEPTOR 1; VIRODHAMINE;

APPETITE; CARDIOVASCULAR SYSTEM; CHEMICAL STRUCTURE; DIET; ENERGY METABOLISM; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GLUCOSE TRANSPORT; HUMAN; LIPID STORAGE; METABOLIC REGULATION; NONHUMAN; OSSIFICATION; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; RECEPTOR DENSITY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; THROMBOGENESIS;

ANIMALS; APPETITE REGULATION; BRAIN; DIETARY FATS; ENDOCANNABINOIDS; ENERGY METABOLISM; FEEDING BEHAVIOR; HOMEOSTASIS; HUMANS; OBESITY; RECEPTOR, CANNABINOID, CB1;

EID: 53249093794     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nutres.2008.08.003     Document Type: Review

References (90)

1. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34 (1988) 605-613
2. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
3. Pertwee R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74 (1997) 129-180
4. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
5. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International Union of Pharmacology: XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 (2002) 161-202
6. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 (2005) 329-332
7. 2+ signals and insulin secretion in pancreatic β-cell. Cell Calcium 39 (2006) 155-162
8. Ofek O., Karsak M., Leclerc N., Fogel M., Frenkel B., Wright K.L., et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A 103 (2006) 696-701
9. Julien B., Grenard P., Teixeira-Clerc F., Van Nhieu J.T., Li L., Karsak M., et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128 (2005) 742-755
10. Steffens S., Veillard N.R., Arnaud C., Pelli G., Burger F., Staub C., et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434 (2005) 782-786
11. Wright K.L., Duncan M., and Sharkey K.A. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 153 (2008) 263-270
12. Pacher P., Batkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58 (2006) 389-462
13. Starowicz K.M., Cristino L., and Di Marzo V. TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr Pharm Des 14 (2008) 42-54
14. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
15. Mechoulama R., Ben-Shabata S., Hanusa L., Ligumskya M., Kaminskib N.E., Schatzd A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 (1995) 83-90
16. Bisogno T., Melck D., Bobrov M., Gretskaya N.M., Bezuglov V.V., De Petrocellis L., et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivationwith cannabimimetic activity in vitro and in vivo. Biochem J 3 (2000) 817-824
17. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A 98 (2001) 3662-3665
18. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301 (2002) 1020-1024
19. Hansen H.S., Moesgaard B., Hansen H.H., and Petersen G. N-Acylethanolamines and precursor phospholipids: relation to cell injury. Chem Phys Lipids 108 (2000) 135-150
20. Willoughby K.A., Moore S.F., Martin B.R., and Ellis E.F. The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282 (1997) 243-247
21. Hillard C.J., Manna S., Greenberg M.J., Di Camelli R., Ross R.A., Stevenson L.A., et al. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289 (1999) 1427-1433
22. Bab I., and Zimmer A. Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol 153 (2008) 182-188
23. Sugiura T., Kondo S., Kishimoto S., Miyashita T., Nakane S., Kodaka T., et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275 (2000) 605-612
24. Sugiura T., Kobayashi Y., Oka S., and Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids 66 (2002) 173-192
25. Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46 (2006) 101-122
26. De Petrocellis L., Cascio M.G., and Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141 (2004) 765-774
27. Fowler C.J., and Jacobsson S.O. Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide: targets for drug development?. Prostaglandins Leukot Essent Fatty Acids 66 (2002) 193-200
28. McFarland M.J., and Barker E.L. Anandamide transport. Pharmacol Ther 104 (2004) 117-135
29. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., and Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides. Nature 384 (1996) 83-87
30. Dinh T.P., Freund T.F., and Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 121 (2002) 149-158
31. Glaser S.T., Abumrad N.A., Fatade F., Kaczocha M., Studholme K.M., and Deutsch D.G. Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A 100 (2003) 4269-4274
32. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., and Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370 (2007) 1706-1713
33. Van Gaal L., Pi-Sunyer X., Després J.P., McCarthy C., and Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 Suppl 2 (2008) S229-S240
34. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab 4 (2006) 341-348
35. Tam J., Ofek O., Fride E., Ledent C., Gabet Y., Müller R., et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 70 (2006) 786-792
36. Wildburger R., Zarkovic N., Egger G., Petek W., Zarkovic K., and Hofer H.P. Basic fibroblast growth factor (BFGF) immunoreactivity as a possible link between head injury and impaired bone fracture healing. Bone Miner 27 (1994) 183-192
37. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413 (2001) 527-531
38. Ishac E.J., Jiang L., Lake K.D., Varga K., Abood M.E., and Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118 (1996) 2023-2028
39. Tam J., Trembovler V., Di Marzo V., Petrosino S., Leo G., Alexandrovich A., et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J 22 (2008) 285-294
40. Karsak M., Cohen-Solal M., Freudenberg J., Ostertag A., Morieux C., Kornak U., et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 14 (2005) 3389-3396
41. Yamada Y., Ando F., and Shimokata H. Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int J Mol Med 19 (2007) 791-801
42. Randall M.D., Harris D., Kendall D.A., and Ralevic V. Cardiovascular effects of cannabinoids. Pharmacol Ther 95 (2002) 191-202
43. Lake K.D., Martin B.R., Kunos G., and Varga K. Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29 (1997) 1204-1210
44. Bátkai S., Pacher P., Osei-Hyiaman D., Radaeva S., Liu J., Harvey-White J., et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110 (2004) 1996-2002
45. Wagner J.A., Varga K., Ellis E.F., Rzigalinski B.A., Martin B.R., and Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390 (1997) 518-521
46. Wagner J.A., Hu K., Bauersachs J., Karcher J., Wiesler M., Goparaju S.K., et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 38 (2001) 2048-2054
47. Varga K., Wagner J.A., Bridgen D.T., and Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12 (1998) 1035-1044
48. Ruilope L.M., Després J.P., Scheen A., Pi-Sunyer X., Mancia G., Zanchetti A., et al. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens 26 (2008) 357-367
49. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
50. Mach F., Montecucco F., and Steffens S. Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol 153 (2008) 290-298
51. Carrier E.J., Kearn C.S., Barkmeier A.J., Breese N.M., Yang W., Nithipatikom K., et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 65 (2004) 999-1007
52. Ashton J.C., Rahman R.M., Nair S.M., Sutherland B.A., Glass M., and Appleton I. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett 412 (2007) 114-117
53. Deusch E., Kress H.G., Kraft B., and Kozek-Langenecker S.A. The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets. Anesth Analg 99 (2004) 1127-1130
54. Bátkai S., Rajesh M., Mukhopadhyay P., Haskó G., Liaudet L., Cravatt B.F., et al. Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 293 (2007) H909-H918
55. Montecucco F., Burger F., Mach F., and Steffens S. The CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol 294 (2008) H1145-H1155
56. 2 cannabinoid receptor agonists attenuate TNF-α-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 153 (2008) 347-357
57. Williams C.M., and Kirkham T.C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 143 (1999) 315-317
58. Kirkham T.C., Williams C.M., Fezza F., and Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136 (2002) 550-557
59. Di Marzo V., Goparaju S.K., Wang L., Liu J., Bátkai S., Járai Z., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
60. Kola B., Farkas I., Christ-Crain M., Wittmann G., Lolli F., Amin F., et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS ONE 3 (2008) e1797
61. Burdyga G., Lal S., Varro A., Dimaline R., Thompson D.G., and Dockray G.J. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 24 (2004) 2708-2715
62. Gómez R., Navarro M., Ferrer B., Trigo J.M., Bilbao A., Del Arco I., et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22 (2002) 9612-9617
63. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Petrocellis L., Cervino C., et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91 (2006) 3171-3180
64. Cota D., Marsicano G., Tschöp M., Grübler Y., Flachskamm C., Schubert M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112 (2003) 423-431
65. Jbilo O., Ravinet-Trillou C., Arnone M., Buisson I., Bribes E., Péleraux A., et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19 (2005) 1567-1569
66. Poirier B., Bidouard J.P., Cadrouvele C., Marniquet X., Staels B., O'Connor S.E., et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7 (2005) 65-72
67. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J.P., Le Fur G., Oury-Donat F., et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63 (2003) 908-914
68. Gary-Bobo M., Elachouri G., Gallas J.F., Janiak P., Marini P., Ravinet-Trillou C., et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46 (2007) 122-129
69. Hildebrandt A.L., Kelly-Sullivan D.M., and Black S.C. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 462 (2003) 125-132
70. Scheen A.J., Finer N., Hollander P., Jensen M.D., Van Gaal L.F., and RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006) 1660-1672
71. Pagano C., Pilon C., Calcagno A., Urbanet R., Rossato M., Milan G., et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 92 (2007) 4810-4819
72. Motaghedi R., and McGraw T.E. The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. Obesity (Silver Spring) (2008) [electronic publication ahead of print]
73. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Bátkai S., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115 (2005) 1298-1305
74. Jeong W.I., Osei-Hyiaman D., Park O., Liu J., Bátkai S., Mukhopadhyay P., et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 7 (2008) 227-235
75. Nakata M., and Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. Regul Pept 145 (2008) 49-53
76. Bermúdez-Silva F.J., Suárez J., Baixeras E., Cobo N., Bautista D., Cuesta-Muñoz A.L., et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 51 (2008) 476-487
77. Liu Y.L., Connoley I.P., Wilson C.A., and Stock M.J. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes 29 (2005) 183-187
78. Cavuoto P., McAinch A.J., Hatzinikolas G., Cameron-Smith D., and Wittert G.A. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 267 (2007) 63-69
79. Nogueiras R., Rohner-Jeanrenaud F., Woods S.C., and Tschöp M.H. The endocannabinoid system and the control of glucose homeostasis. J Neuroendocrinol 20 Suppl 1 (2008) 147-151
80. Harrold J.A., Elliott J.C., King P.J., Widdowson P.S., and Williams G. Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food?. Brain Res 952 (2002) 232-238
81. Petersen G., Sørensen C., Schmid P.C., Artmann A., Tang-Christensen M., Hansen S.H., et al. Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors. Biochim Biophys Acta 1761 (2006) 143-150
82. Rodríguez de Fonseca F., Navarro M., Gómez R., Escuredo L., Nava F., Fu J., et al. An anorexic lipid mediator regulated by feeding. Nature 414 (2001) 209-212
83. Clandinin M.T., Field C.J., Hargreaves K., Morson L., and Zsigmond E. Role of diet fat in subcellular structure and function. Can J Physiol Pharmacol 63 (1985) 546-556
84. Berger A., Crozier G., Bisogno T., Cavaliere P., Innis S., and Di Marzo V. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc Natl Acad Sci U S A 98 (2001) 6402-6406
85. Watanabe S., Doshi M., and Hamazaki T. n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids 69 (2003) 51-59
86. Artmann A., Petersen G., Hellgren L.I., Boberg J., Skonberg C., Nellemann C., et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 1781 (2008) 200-212
87. Matias I., Carta G., Murru E., Petrosino S., Banni S., and Di Marzo V. Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys Acta 1781 (2008) 52-60
88. Starowicz K.M., Cristino L., Matias I., Capasso R., Racioppi A., Izzo A.A., et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 16 (2008) 553-565
89. Matias I., Petrosino S., Racioppi A., Capasso R., Izzo A.A., and Di Marzo V. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effects of high fat diets. Mol Cell Endocrinol 286 1-2 Suppl 1 (2008) S66-S78
90. Tsuyama S., Oikawa D., Yamasaki Y., Takagi S., Ando H., and Furuse M. Expression of endocannabinoid synthetic enzyme mRNAs is correlated with cannabinoid 1 receptor mRNA in the mouse brain. Nutr Neurosci 10 (2007) 45-50